Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6474573 | 0.79 | CSNK2A1 (0.38) | CSNK2A1ADORA3HTTPARP1YTHDC1 | |
| SCHEMBL7526936 | 0.79 | CDK1 (0.35) | CDK1ALDH1A1 | |
| SCHEMBL12592351 | 0.79 | CSNK2A1 (0.38) | CSNK2A1ADORA3HTTPARP1YTHDC1 | |
| SCHEMBL20564 | 0.79 | ADORA3 (0.38) | CSNK2A1ADORA3PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL2953678 | 0.79 | ADORA3 (0.38) | CSNK2A1ADORA3PARP1ALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL31329224 | 0.78 | CSNK2A1 (0.37) | CSNK2A1ADORA3HTTPARP1YTHDC1 | |
| SCHEMBL12592352 | 0.76 | ADORA3 (0.35) | CSNK2A1ADORA3PARP1ALDH1A1L3MBTL1 | |
| SCHEMBL6358280 | 0.72 | CSNK2A1 (0.36) | CSNK2A1ADORA3HTTPARP1ALDH1A1 | |
| SCHEMBL5437633 | 0.71 | LMNA (0.41) | CDK1CSNK2A1ADORA3HTTYTHDC1 | |
| SCHEMBL953009 | 0.69 | NUDT1 (0.41) | ADORA3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2022-05-12 | — | — | US | disclosed |
| WO-2020186220-A1 | COMPOUNDS AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR | IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2020-09-17 | — | — | WO | disclosed |
| WO-2017197624-A1 | PURINE-SCAFFOLD TLR7 LIGANDS AND CONJUGATE THEREOF | SHENZHEN HORNETCORN BIOTECHNOLOGY COMPANY,CO., LTD (CN) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144838-A1 | Compounds as Inhibitors of Macrophage Migration Inhibitory Factor | MIF, MMP12, SLC11A2 | CDK1 3328/4885CSNK2A1 1881/4885ADORA3 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.